Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway

Experimental Cell Research

Volumn 302, Issue 2, 2005, Pages 162-169

  Agner, Jeppe ^a   Falck, Jacob ^a   Lukas, Jiri ^a   Bartek, Jiri ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Anticancer drugs; Cancer; Cdc25A; Cell cycle; Checkpoint; Chk1 2 kinase; Cyclin CDK kinases; DNA damage; DNA synthesis

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PROTEIN TYROSINE PHOSPHATASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGRADATION KINETICS; DNA DAMAGE; DNA REPLICATION; DNA SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

MAMMALIA;

EID: 9244231805     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.08.035     Document Type: Article

References (39)

1. B.B. Zhou, and J. Bartek Targeting the checkpoint kinases: chemosensitization versus chemoprotection Nat. Rev., Cancer 4 2004 216 225
2. R.T. Abraham Cell cycle checkpoint signaling through the ATM and ATR kinases Genes Dev. 15 2001 2177 2196
3. B.B. Zhou, and S.J. Elledge The DNA damage response: putting checkpoints in perspective Nature 408 2000 433 439
4. Y. Shiloh ATM and related protein kinases: safeguarding genome integrity Nat. Rev., Cancer 3 2003 155 168
5. J. Bartek, and J. Lukas Mammalian G1- and S-phase checkpoints in response to DNA damage Curr. Opin. Cell Biol. 13 2001 738 747
6. J. Bartek, and J. Lukas Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cells 3 2003 421 429
7. L. Busino, M. Chiesa, G.F. Draetta, and M. Donzelli Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis Oncogene 23 2004 2050 2056
8. J. Falck, N. Mailand, R.G. Syljuasen, J. Bartek, and J. Lukas The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis Nature 410 2001 842 847
9. N. Mailand, J. Falck, C. Lukas, R. Syljuasen, M. Welcker, J. Bartek, and J. Lukas Rapid destruction of human Cdc25A in response to DNA damage Science 288 2000 1425 1429
10. M. Molinari, C. Mercurio, J. Dominguez, F. Goubin, and G.F. Draetta Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis EMBO Rep. 1 2000 71 79
11. N. Mailand, A.V. Podtelejnikov, A. Groth, M. Mann, J. Bartek, and J. Lukas Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability EMBO J. 21 2002 5911 5920
12. A. Goloudina, H. Yamaguchi, D.B. Chervyakova, E. Appella, A.J. Fornace Jr., and D.V. Bulavin Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint Cell Cycle 2 2003 473 478
13. I. Hassepass, R. Voit, and I. Hoffmann Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint J. Biol. Chem. 278 2003 29824 29829
14. C.S. Sorensen, R.G. Syljuasen, J. Falck, T. Schroeder, L. Ronnstrand, K.K. Khanna, B.B. Zhou, J. Bartek, and J. Lukas Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A Cancer Cells 3 2003 247 258
15. H. Zhao, J.L. Watkins, and H. Piwnica-Worms Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints Proc. Natl. Acad. Sci. U. S. A. 99 2002 14795 14800
16. L. Busino, M. Donzelli, M. Chiesa, D. Guardavaccaro, D. Ganoth, N.V. Dorrello, A. Hershko, M. Pagano, and G.F. Draetta Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage Nature 426 2003 87 91
17. J. Jin, T. Shirogane, L. Xu, G. Nalepa, J. Qin, S.J. Elledge, and J.W. Harper SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase Genes Dev. 17 2003 3062 3074
18. J. Falck, J.H. Petrini, B.R. Williams, J. Lukas, and J. Bartek The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways Nat. Genet. 30 2002 290 294
19. P. Jordan, and M. Carmo-Fonseca Molecular mechanisms involved in cisplatin cytotoxicity Cell. Mol. Life Sci. 57 2000 1229 1235
20. S. Sangrajrang, and A. Fellous Taxol resistance Chemotherapy 46 2000 327 334
21. J. Lukas, D. Jadayel, J. Bartkova, E. Nacheva, M.J. Dyer, M. Strauss, and J. Bartek BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation Oncogene 9 1994 2159 2167
22. H. Zhao, and H. Piwnica-Worms ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1 Mol. Cell. Biol. 21 2001 4129 4139
23. S. Banin, L. Moyal, S. Shieh, Y. Taya, C.W. Anderson, L. Chessa, N.I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv Enhanced phosphorylation of p53 by ATM in response to DNA damage Science 281 1998 1674 1677
24. R.S. Tibbetts, K.M. Brumbaugh, J.M. Williams, J.N. Sarkaria, W.A. Cliby, S.Y. Shieh, Y. Taya, C. Prives, and R.T. Abraham A role for ATR in the DNA damage-induced phosphorylation of p53 Genes Dev. 13 1999 152 157
25. C. Stevens, L. Smith, and N.B. La Thangue Chk2 activates E2F-1 in response to DNA damage Nat. Cell Biol. 5 2003 401 409
26. B. Shan, A.A. Farmer, and W.H. Lee The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis Cell Growth Differ. 7 1996 689 697
27. G. Iliakis, Y. Wang, J. Guan, and H. Wang DNA damage checkpoint control in cells exposed to ionizing radiation Oncogene 22 2003 5834 5847
28. W.A. Cliby, K.A. Lewis, K.K. Lilly, and S.H. Kaufmann S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function J. Biol. Chem. 277 2002 1599 1606
29. D. Theard, M. Coisy, B. Ducommun, P. Concannon, and J.M. Darbon Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR Biochem. Biophys. Res. Commun. 289 2001 1199 1204
30. Z. Xiao, Z. Chen, A.H. Gunasekera, T.J. Sowin, S.H. Rosenberg, S. Fesik, and H. Zhang Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents J. Biol. Chem. 278 2003 21767 21773
31. D.A. Burden, and N. Osheroff Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme Biochim. Biophys. Acta 1400 1998 139 154
32. Y. Pommier, P. Pourquier, Y. Fan, and D. Strumberg Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme Biochim. Biophys. Acta 1400 1998 83 105
33. M. Gatei, K. Sloper, C. Sorensen, R. Syljuasen, J. Falck, K. Hobson, K. Savage, J. Lukas, B.B. Zhou, J. Bartek, and K.K. Khanna Ataxia-telangiectasia- mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation J. Biol. Chem. 278 2003 14806 14811
34. X. Wang, J. Khadpe, B. Hu, G. Iliakis, and Y. Wang An overactivated ATR/CHK1 pathway is responsible for the prolonged G2 accumulation in irradiated AT cells J. Biol. Chem. 278 2003 30869 30874
35. Y. Pommier, C. Redon, A.V. Rao, J.A. Seiler, O. Sordet, H. Takemura, S. Antony, L.-H. Meng, Z.-Y. Liao, G. Kohlhagen, H.-L. Zhang, and K.W. Kohn Repair of and checkpoint response to topoisomerase I-mediated DNA damage Mutat. Res. 532 2003 173 203
36. M.V. Blagosklonny, T.W. Schulte, P. Nguyen, E.G. Mimnaugh, J. Trepel, and L. Neckers Taxol induction of p21WAF1 and p53 requires c-raf-1 Cancer Res. 55 1995 4623 4626
37. P. Giannakakou, D.L. Sackett, Y. Ward, K.R. Webster, M.V. Blagosklonny, and T. Fojo p53 is associated with cellular microtubules and is transported to the nucleus by dynein Nat. Cell Biol. 2 2000 709 717
38. P.T. Yazdi, Y. Wang, S. Zhao, N. Patel, E.Y. Lee, and J. Qin SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint Genes Dev. 16 2002 571 582
39. S.T. Kim, B. Xu, and M.B. Kastan Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage Genes Dev. 16 2002 560 570